

RADIUS HEALTH, INC.

Filed by
BB BIOTECH AG

FORM SC 13D/A (Amended Statement of Beneficial Ownership)

Filed 06/01/17

Address	ATTN: CHIEF FINANCIAL OFFICER 950 WINTER STREET WALTHAM, MA 02451
Telephone	617-551-4000
CIK	0001428522
Symbol	RDUS
SIC Code	0000 - Unknown
Industry	Biotechnology & Medical Research
Sector	Healthcare
Fiscal Year	12/31

**UNITED STATES
SECURITIES AND EXCHANGE COMMISSION**
Washington, D.C. 20549

SCHEDULE 13D

**Under the Securities Exchange Act of 1934
(Amendment No. 8)***

Radius Health, Inc.
(Name of Issuer)

Common Stock, \$0.0001 par value
(Title of Class of Securities)

750469108
(CUSIP Number)

**BB Biotech AG
Ivo Betschart
Schwertstrasse 6
CH-8200 Schaffhausen, Switzerland
+41 44 267 67 00**
(Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)

May 25, 2017
(Date of Event Which Requires Filing of this Statement)

If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box.

Note: Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. See §240.13d-7 for other parties to whom copies are to be sent.

* The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

The information required on the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

1.	Names of Reporting Persons I.R.S. Identification Nos. of Above Persons (Entities Only) BB Biotech AG
2.	Check the Appropriate Box if a Member of a Group (a) <input checked="" type="checkbox"/> (b) <input type="checkbox"/>
3.	SEC Use Only
4.	Source of Funds WC
5.	Check if Disclosure of Legal Proceedings Is Required Pursuant to Items 2(d) or 2(e) <input type="checkbox"/>
6.	Citizenship or Place of Organization Switzerland
NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH	7. Sole Voting Power 0 shares
	8. Shared Voting Power 5,217,322 (1)
	9. Sole Dispositive Power 0 shares
	10. Shared Dispositive Power 5,217,322 (1)
11.	Aggregate Amount Beneficially Owned by Each Reporting Person 5,217,322 (1)
12.	Check if the Aggregate Amount in Row (11) Excludes Certain Shares <input type="checkbox"/>
13.	Percent of Class Represented by Amount in Row (11) 12.0%
14.	Type of Reporting Person HC, CO

(1) Includes 178,523 shares of Common Stock that may be issued upon exercise of the Biotech Growth Warrant and the Biotech Growth New Warrant.

Schedule 13D (Amendment No. 8)

EXPLANATORY NOTE: This Amendment No. 8 to Schedule 13D amends the statement on Schedule 13D relating to shares of common stock, \$0.0001 par value (the “Common Stock”) of Radius Health, Inc. (the “Issuer”), initially filed by BB Biotech AG and Biotech Growth, NV (collectively, the “Reporting Persons”) with the Securities and Exchange Commission on June 3, 2011 (together with all amendments thereto, this “Schedule 13D”).

Each capitalized term used and not defined herein shall have the meaning assigned to such term in prior amendments to this Schedule 13D. Except as otherwise provided herein, each Item of this Schedule 13D remains unchanged.

Item 3. Source and Amount of Funds or Other Consideration

Item 3 is hereby supplemented to add the following:

Between March 22, 2017 and May 30, 2017, the Reporting Persons acquired an additional 498,400 shares of the Issuer’s Common Stock (the “Second Additional Shares”) on the open market. The increase of 498,400 shares held by the Reporting Persons resulted in an approximate 1.1% increase in percentage ownership of the outstanding shares of the Issuer’s Common Stock held by the Reporting Persons since the filing of Amendment No. 7 to this Schedule 13D with the Securities and Exchange Commission on March 22, 2017. The purchases of the Second Additional Shares were made with the working capital of BB Biotech and the aggregate amount of funds expended, excluding commissions, to acquire the Second Additional Shares was US \$17,411,012.56.

Item 4. Purpose of Transaction

Item 4 is hereby supplemented to add the following:

The Reporting Persons acquired the Second Additional Shares for investment purposes.

Item 5. Interest in Securities of the Issuer

Item 5 is hereby amended and restated in its entirety as follows:

- (a) Assuming the exercise of the Biotech Growth Warrant and the exercise of the Biotech Growth New Warrant, Biotech Growth is the record owner of 5,217,322 shares of Common Stock. To the best knowledge of BB Biotech and Biotech Growth, no director or executive officer of BB Biotech or Biotech Growth owns any shares of the Common Stock.
- (b) Regarding the number of shares as to which such person has:
 - (i) sole power to vote or to direct the vote:
See Line 7 of cover sheets.
 - (ii) shared power to vote or to direct the vote:
See Line 8 of cover sheets.
 - (iii) sole power to dispose or to direct the disposition:
See Line 9 of cover sheets.
 - (iv) shared power to dispose or to direct the disposition:
See Line 10 of cover sheets.
- (c) Except as set forth in Item 3 above, none of the Reporting Persons has effected any transaction in the Common Stock of the Issuer during the last 60 days. To the best knowledge of the Reporting Persons, no director or executive officer of BB Biotech and Biotech Growth has effected any transaction in the Common Stock during the last 60 days.
- (d) No other person is known to have the right to receive or the power to direct the receipt of dividends from, or any proceeds from the sale of, shares beneficially owned by any of the Reporting Persons.
- (e) Not Applicable.

Item 7. Material to Be Filed as Exhibits

Item 7 of the Schedule 13D is amended and supplemented as follows:

Exhibit 1 – Agreement regarding joint filing of Schedule 13D*

* Previously filed as an exhibit to BB Biotech and Biotech Growth's Schedule 13D filed with the SEC on June 3, 2011.

